NCT00934986

Natural Killer Cells Function in Patients With Chronic Lymphocytic Leukemia

Study of Natural Killer Cells Function in Untreated Patients With Chronic Lymphocytic Leukemia

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: Institut Paoli-Calmettes · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Purpose: The involvement of Natural Killer cells (NK) in the efficiency of the treatment in lymphoma and the beginning of new therapies based on function and activation of NK, justify an improvement of knowledge about the status of the population of NK (number, function, genic expression) in Chronic Lymphocytic Leukemia (CLL).

Detailed description

Method: prospective, monocentric, descriptive study Primary objective: Evaluation of the expression and function of receptors activator of NK cell (KIRs) in patients with CLL at stage A with therapeutic abstention, or stage B or C which require a treatment. Secondary objectives: Measure of the evolution of cytotoxic function of NK cells and theirs biomarkers of activation when the patient receives an immunochemotherapy with Rituximab/ Fludarabine/ Cyclophosphamide (RCF). Verification, by analysis, of functions and biomarkers of the adaptive and innate immunity

Conditions

• Chronic Lymphocytic Leukemia

Interventions

Type	Name	Description
OTHER	Surface expression of functional biomarkers of the NK cell	An extra blood sample of 40 ml is required : * Stage A patient who does not require a treatment: one sample the day of enrollment. * Stage B or C patient who require RFC treatment: sample at D0 of the 1st and 4th cure of RFC, and 3 months after the end of the treatment.

Timeline

• Start date: 2008-03-01
• Primary completion: 2010-03-01
• Completion: 2010-09-01
• First posted: 2009-07-08
• Last updated: 2011-09-14

Locations

1 site across 1 country: France